Regeneron approval brings relief for 'second skeleton' bone disorder.
Regeneron has received approval for a treatment for the 'second skeleton' bone disorder, a condition in which bone forms progressively in soft tissue. The approval marks the first regulatory decision for this indication for the company. No dosing, pricing or trial details were disclosed.
Why it matters: First approval for a Regeneron therapy in a rare progressive bone disorder.